APA (7th ed.) Citation

Spring, L. M., Scarpetti, L., Medford, A. J., Niemierko, A., Comander, A., Mulvey, T., . . . Bardia, A. (2025). Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER). NPJ breast cancer, 11(1), 2-9. https://doi.org/10.1038/s41523-024-00708-5

Chicago Style (17th ed.) Citation

Spring, Laura M., et al. "Adjuvant Endocrine Therapy with Cyclin-dependent Kinase 4/6 Inhibitor, Ribociclib, for Localized Hormone Receptor-positive/HER2– Breast Cancer (LEADER)." NPJ Breast Cancer 11, no. 1 (2025): 2-9. https://doi.org/10.1038/s41523-024-00708-5.

MLA (9th ed.) Citation

Spring, Laura M., et al. "Adjuvant Endocrine Therapy with Cyclin-dependent Kinase 4/6 Inhibitor, Ribociclib, for Localized Hormone Receptor-positive/HER2– Breast Cancer (LEADER)." NPJ Breast Cancer, vol. 11, no. 1, 2025, pp. 2-9, https://doi.org/10.1038/s41523-024-00708-5.